05:42 PM EDT, 08/05/2025 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) reported Q2 loss late Tuesday of $1.17 per diluted share, narrowing from a loss of $1.52 a year earlier.

Analysts surveyed by FactSet expected a loss of $1.30.

Revenue for the quarter ended June 30 was $166.5 million, up from $147 million a year earlier.

Analysts polled by FactSet expected $162 million.

The company reiterated its full-year 2025 revenue guidance of $640 million to $670 million.

Analysts expect $652.3 million.